ProCyte 3rd quaretr results

27 November 1995

- At ProCyte Corporation revenues declined from $1.3 million in the 1994 third quarter to $684,382. In the first nine months of 1995 revenues were up 6.5% to $3.4 million. The net loss for the three-month period was $1.4 million or $0.11, a reduction on the previous year. In the nine-month period the loss was $4.2 million, compared with $9.2 million. Research, development and regulatory expenses decreased around 73% from the year-ago quarter, primarily due to completion of the Phase III study of Iamin gel.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight